共 166 条
[1]
Nash P(2006)Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study Dermatology (Basel, Switzerland) 212 238-249
[2]
Thaci D(2004)Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression Arthritis Rheum 50 2264-2272
[3]
Behrens F(2005)Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial Arthritis Rheum 52 3279-3289
[4]
Falk F(2005)Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial Ann Rheum Dis 64 1150-1157
[5]
Kaltwasser JP(2012)Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial Arthritis Rheum 64 2504-2517
[6]
Mease PJ(2009)Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study Arthritis Rheum 60 976-986
[7]
Kivitz AJ(2014)Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) Ann Rheum Dis 73 48-55
[8]
Burch FX(2013)Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial Lancet (London, England) 382 780-789
[9]
Mease PJ(2014)Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial Ann Rheum Dis 73 990-999
[10]
Gladman DD(2014)Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor Ann Rheum Dis 73 1020-1026